OBJECTIVE To explore the curative effect and mechanism of Yiqi Huoxue decoction in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome.METHODS The patients with coronary heart disease ...OBJECTIVE To explore the curative effect and mechanism of Yiqi Huoxue decoction in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome.METHODS The patients with coronary heart disease of Qi deficiency and blood stasis syndrome were treated with Yiqi Huoxue decoction for 3 months,and the changes of cardiac function were observed.61 serum samples(including 29 cases of disease group and 32 cases of Yiqi Huoxue expression group)were analyzed by non labeled proteomics.The disease group was used as the control group,and the protein with expression level difference of more than 1.2 folds(P<0.05)was screened.The molecular function,biological pathway and protein interaction of the different proteins were analyzed by bioinformatics,so as to identify the molecular and biological pathway of Yiqi Huoxue decoction in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome.RESULTS Clinical treatment found that Yiqi Huoxue decoction can improve TCM syndrome score and left ventricular ejection fraction,regulate blood glucose and blood lipid levels,prolong thrombin time,and improve heart function.The results of proteomic quantitative analysis showed that there were 69 proteins with different expression levels in the disease group.Bioinformatics analysis results showed that Yiqi Huoxue decoction may regulate ApoA1,alpha-2 and other proteins to act on HDL assembly,platelet degradation,PI3K Akt signaling pathway,and then play a therapeutic role in coronary heart disease with Qi deficiency and blood stasis syndrome.CONCLUSION Yiqi Huoxue decoction can effectively improved the heart function decline caused by Qi deficiency and blood stasis syndrome of coronary heart disease.It mainly act on energy metabolism and platelet activation pathway by activating HDL assembly and platelet degradation signal pathway proteins.This study can provide reference for the follow-up treatment mechanism of Qi deficiency and blood stasis syndrome of coronary heart disease.展开更多
目的考察麻黄附子细辛汤联合非免疫抑制治疗对脾肾阳虚型局灶节段性肾小球硬化患者的临床疗效。方法60例患者随机分为对照组和观察组,每组30例,对照组给予非免疫抑制治疗,观察组在对照组基础上加用麻黄附子细辛汤,疗程24周。检测临床疗...目的考察麻黄附子细辛汤联合非免疫抑制治疗对脾肾阳虚型局灶节段性肾小球硬化患者的临床疗效。方法60例患者随机分为对照组和观察组,每组30例,对照组给予非免疫抑制治疗,观察组在对照组基础上加用麻黄附子细辛汤,疗程24周。检测临床疗效、中医证候疗效、中医证候评分、24 h UTP、ALB、eGFR、Nephrin、Podocin、安全性指标变化。结果观察组总有效率、中医证候有效率高于对照组(P<0.05)。治疗后,2组中医证候评分、24 h UTP、Nephrin、Podocin降低(P<0.05),ALB升高(P<0.05),以观察组更明显(P<0.05)。2组未发生明显不良反应。结论麻黄附子细辛汤联合非免疫抑制治疗可安全有效地改善脾肾阳虚型局灶节段性肾小球硬化患者中医证候,其作用机制可能与缓解足细胞损伤有关。展开更多
目的基于非线性混合效应模型探讨慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)气虚证演变影响因素,以期为相关研究提供方法学范例。方法制定《慢性阻塞性肺疾病气虚证演变影响因素研究调查表》,在全国10家三甲医院动...目的基于非线性混合效应模型探讨慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)气虚证演变影响因素,以期为相关研究提供方法学范例。方法制定《慢性阻塞性肺疾病气虚证演变影响因素研究调查表》,在全国10家三甲医院动态采集650例COPD患者的急性加重期第1天、第14天、危险窗期第1天、第28天、稳定期第1天、第90天临床资料;采用SAS 9.4软件,通过PROC NLMIXED过程,收集性别、年龄等8个基线数据;占比最高的冠心病、糖尿病、高血压3个合并症;风寒证、痰热证等9个兼夹证候作为固定效应,将个体水平作为随机效应,逐步拟合模型,筛选气虚证在疾病全程发生发展过程中的影响因素。结果共纳入合格病例637例,动态采集其急性加重期第1天、第14天、危险窗期第1天、第28天、稳定期第1天、第90天临床资料,发现前一年急性加重次数、饮酒、合并高血压、冠心病、兼夹血瘀证、阴虚证、阳虚证、6分钟步行距离、改良版英国医学研究委员会呼吸困难问卷(Modified Medical Research Council dyspnea questionnaire,mMRC)影响气虚证的演变(P<0.05)。结论采用非线性混合效应模型从复杂多时点动态数据中揭示了影响气虚证演变的相关因素,为相关研究提供了方法学借鉴。展开更多
基金National Natural Science Foundation of China(82030124)and National Key Basic Research Special Foundation of China(2015CB554400)。
文摘OBJECTIVE To explore the curative effect and mechanism of Yiqi Huoxue decoction in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome.METHODS The patients with coronary heart disease of Qi deficiency and blood stasis syndrome were treated with Yiqi Huoxue decoction for 3 months,and the changes of cardiac function were observed.61 serum samples(including 29 cases of disease group and 32 cases of Yiqi Huoxue expression group)were analyzed by non labeled proteomics.The disease group was used as the control group,and the protein with expression level difference of more than 1.2 folds(P<0.05)was screened.The molecular function,biological pathway and protein interaction of the different proteins were analyzed by bioinformatics,so as to identify the molecular and biological pathway of Yiqi Huoxue decoction in the treatment of coronary heart disease with Qi deficiency and blood stasis syndrome.RESULTS Clinical treatment found that Yiqi Huoxue decoction can improve TCM syndrome score and left ventricular ejection fraction,regulate blood glucose and blood lipid levels,prolong thrombin time,and improve heart function.The results of proteomic quantitative analysis showed that there were 69 proteins with different expression levels in the disease group.Bioinformatics analysis results showed that Yiqi Huoxue decoction may regulate ApoA1,alpha-2 and other proteins to act on HDL assembly,platelet degradation,PI3K Akt signaling pathway,and then play a therapeutic role in coronary heart disease with Qi deficiency and blood stasis syndrome.CONCLUSION Yiqi Huoxue decoction can effectively improved the heart function decline caused by Qi deficiency and blood stasis syndrome of coronary heart disease.It mainly act on energy metabolism and platelet activation pathway by activating HDL assembly and platelet degradation signal pathway proteins.This study can provide reference for the follow-up treatment mechanism of Qi deficiency and blood stasis syndrome of coronary heart disease.
文摘目的考察麻黄附子细辛汤联合非免疫抑制治疗对脾肾阳虚型局灶节段性肾小球硬化患者的临床疗效。方法60例患者随机分为对照组和观察组,每组30例,对照组给予非免疫抑制治疗,观察组在对照组基础上加用麻黄附子细辛汤,疗程24周。检测临床疗效、中医证候疗效、中医证候评分、24 h UTP、ALB、eGFR、Nephrin、Podocin、安全性指标变化。结果观察组总有效率、中医证候有效率高于对照组(P<0.05)。治疗后,2组中医证候评分、24 h UTP、Nephrin、Podocin降低(P<0.05),ALB升高(P<0.05),以观察组更明显(P<0.05)。2组未发生明显不良反应。结论麻黄附子细辛汤联合非免疫抑制治疗可安全有效地改善脾肾阳虚型局灶节段性肾小球硬化患者中医证候,其作用机制可能与缓解足细胞损伤有关。
文摘目的基于非线性混合效应模型探讨慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)气虚证演变影响因素,以期为相关研究提供方法学范例。方法制定《慢性阻塞性肺疾病气虚证演变影响因素研究调查表》,在全国10家三甲医院动态采集650例COPD患者的急性加重期第1天、第14天、危险窗期第1天、第28天、稳定期第1天、第90天临床资料;采用SAS 9.4软件,通过PROC NLMIXED过程,收集性别、年龄等8个基线数据;占比最高的冠心病、糖尿病、高血压3个合并症;风寒证、痰热证等9个兼夹证候作为固定效应,将个体水平作为随机效应,逐步拟合模型,筛选气虚证在疾病全程发生发展过程中的影响因素。结果共纳入合格病例637例,动态采集其急性加重期第1天、第14天、危险窗期第1天、第28天、稳定期第1天、第90天临床资料,发现前一年急性加重次数、饮酒、合并高血压、冠心病、兼夹血瘀证、阴虚证、阳虚证、6分钟步行距离、改良版英国医学研究委员会呼吸困难问卷(Modified Medical Research Council dyspnea questionnaire,mMRC)影响气虚证的演变(P<0.05)。结论采用非线性混合效应模型从复杂多时点动态数据中揭示了影响气虚证演变的相关因素,为相关研究提供了方法学借鉴。
